143 related articles for article (PubMed ID: 34017080)
41. Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy.
Smith MP; Brunton H; Rowling EJ; Ferguson J; Arozarena I; Miskolczi Z; Lee JL; Girotti MR; Marais R; Levesque MP; Dummer R; Frederick DT; Flaherty KT; Cooper ZA; Wargo JA; Wellbrock C
Cancer Cell; 2016 Mar; 29(3):270-284. PubMed ID: 26977879
[TBL] [Abstract][Full Text] [Related]
42. Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition.
Sharma R; Fedorenko I; Spence PT; Sondak VK; Smalley KS; Koomen JM
J Proteome Res; 2016 Dec; 15(12):4476-4489. PubMed ID: 27934295
[TBL] [Abstract][Full Text] [Related]
43. Genomic deletions explain the generation of alternative BRAF isoforms conferring resistance to MAPK inhibitors in melanoma.
Aya F; Lanuza-Gracia P; González-Pérez A; Bonnal S; Mancini E; López-Bigas N; Arance A; Valcárcel J
Cell Rep; 2024 Apr; 43(4):114048. PubMed ID: 38614086
[TBL] [Abstract][Full Text] [Related]
44. T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAF
Barceló C; Sisó P; Maiques O; García-Mulero S; Sanz-Pamplona R; Navaridas R; Megino C; Felip I; Urdanibia I; Eritja N; Soria X; Piulats JM; Penin RM; Dolcet X; Matías-Guiu X; Martí RM; Macià A
J Invest Dermatol; 2020 Jun; 140(6):1253-1265. PubMed ID: 31877318
[TBL] [Abstract][Full Text] [Related]
45. Role of Flavonoids in the Prevention of AhR-Dependent Resistance During Treatment with BRAF Inhibitors.
Leclair HM; Tardif N; Paris A; Galibert MD; Corre S
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708687
[TBL] [Abstract][Full Text] [Related]
46. Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF.
Kim JH; Ahn JH; Lee M
Cancer Res Treat; 2017 Oct; 49(4):947-959. PubMed ID: 28052651
[TBL] [Abstract][Full Text] [Related]
47. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
[TBL] [Abstract][Full Text] [Related]
48. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
49. PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation.
Sabbatino F; Wang Y; Wang X; Flaherty KT; Yu L; Pepin D; Scognamiglio G; Pepe S; Kirkwood JM; Cooper ZA; Frederick DT; Wargo JA; Ferrone S; Ferrone CR
Oncotarget; 2014 Apr; 5(7):1926-41. PubMed ID: 24732172
[TBL] [Abstract][Full Text] [Related]
50. Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib.
Krayem M; Journe F; Wiedig M; Morandini R; Sales F; Awada A; Ghanem G
Eur J Cancer; 2014 May; 50(7):1310-20. PubMed ID: 24559688
[TBL] [Abstract][Full Text] [Related]
51. Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy.
Talebi A; Dehairs J; Rambow F; Rogiers A; Nittner D; Derua R; Vanderhoydonc F; Duarte JAG; Bosisio F; Van den Eynde K; Nys K; Pérez MV; Agostinis P; Waelkens E; Van den Oord J; Fendt SM; Marine JC; Swinnen JV
Nat Commun; 2018 Jun; 9(1):2500. PubMed ID: 29950559
[TBL] [Abstract][Full Text] [Related]
52. Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance.
Sandri S; Watanabe LRM; Oliveira EA; Faião-Flores F; Migliorini S; Tiago M; Felipe-Silva A; Vazquez VL; da Costa Souza P; Consolaro MEL; Campa A; Maria-Engler SS
Pharmacol Res; 2020 Sep; 159():104998. PubMed ID: 32535222
[TBL] [Abstract][Full Text] [Related]
53. Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas.
Garandeau D; Noujarède J; Leclerc J; Imbert C; Garcia V; Bats ML; Rambow F; Gilhodes J; Filleron T; Meyer N; Brayer S; Arcucci S; Tartare-Deckert S; Ségui B; Marine JC; Levade T; Bertolotto C; Andrieu-Abadie N
Mol Cancer Ther; 2019 Feb; 18(2):289-300. PubMed ID: 30482853
[TBL] [Abstract][Full Text] [Related]
54. Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors.
Hao X; Falo Iii LD; Chen G; Zhang J; Carey CD; Storkus WJ; Falo LD; You Z
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408093
[TBL] [Abstract][Full Text] [Related]
55. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.
Lito P; Saborowski A; Yue J; Solomon M; Joseph E; Gadal S; Saborowski M; Kastenhuber E; Fellmann C; Ohara K; Morikami K; Miura T; Lukacs C; Ishii N; Lowe S; Rosen N
Cancer Cell; 2014 May; 25(5):697-710. PubMed ID: 24746704
[TBL] [Abstract][Full Text] [Related]
56. BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma.
Li YY; Wu C; Chen SM; Shah SS; Wangpaichitr M; Feun LG; Kuo MT; Suarez M; Prince J; Savaraj N
Oncotarget; 2016 Apr; 7(14):17665-80. PubMed ID: 26771234
[TBL] [Abstract][Full Text] [Related]
57. Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma.
Patel A; Garcia LF; Mannella V; Gammon L; Borg TM; Maffucci T; Scatolini M; Chiorino G; Vergani E; Rodolfo M; Maurichi A; Posch C; Matin RN; Harwood CA; Bergamaschi D
Cancer Res; 2020 Jun; 80(12):2676-2688. PubMed ID: 32291316
[TBL] [Abstract][Full Text] [Related]
58. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
[TBL] [Abstract][Full Text] [Related]
59. miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways.
Sun X; Li J; Sun Y; Zhang Y; Dong L; Shen C; Yang L; Yang M; Li Y; Shen G; Tu Y; Tao J
Oncotarget; 2016 Aug; 7(33):53558-53570. PubMed ID: 27448964
[TBL] [Abstract][Full Text] [Related]
60. Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma.
Jain A; Tripathi R; Turpin CP; Wang C; Plattner R
Oncogene; 2017 Aug; 36(32):4585-4596. PubMed ID: 28368422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
